Sandoz
Coverage of Sandoz in the Nexus archive.
- STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Sandoz agreed to pay $478.5 million to settle allegations of price-fixing generic drugs, including $400 million over seven years to states and $28.5 million to resellers. The company denied wrongdoing as part of a long-running legal battle with states and resellers over inflated drug prices.
- EU sieht sich von Trumps neuen Generika-Zöllen nicht betroffen
The European Commission states that EU generic drugs are likely excluded from Trump's proposed 100% tariffs due to the 2025 Turnberry trade agreement, which mandates a 0% duty via the Most-Favored-Nation (MFN) clause. Trump's plan to impose tariffs on generics from 2028 aims to revive U.S. pharmaceutical production, but EU officials emphasize the agreement protects EU exports. The EU warns of potential retaliatory measures if the U.S. violates the accord.
- EU says Trump’s new generic drug tariffs won’t hit its exports
The European Commission claims EU generic medicines will be exempt from Trump’s proposed 100% tariffs starting 2028, citing the 2025 Turnberry trade deal that ensures a 0% most-favored-nation tariff rate. Trump’s plan aims to boost U.S. pharmaceutical production but faces EU assertions that the deal protects European exports from higher levies.
- Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply
Sandoz warns that cheap Chinese imports are threatening Europe's antibiotic supply. The chief executive states the continent risks losing critical medicine capacity without stronger protections.